| Samar J Hajj, MD | |
|
579a Cranbury Rd, East Brunswick, NJ 08816-5426 | |
| (732) 390-0040 | |
| (732) 955-8874 |
| Full Name | Samar J Hajj |
|---|---|
| Gender | Female |
| Speciality | Nuclear Medicine |
| Experience | 16 Years |
| Location | 579a Cranbury Rd, East Brunswick, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073949780 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | 25MA11754100 (New Jersey) | Secondary |
| 207U00000X | Nuclear Medicine | 25MA11754100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Wood Johnson University Hospital - Somerset | Somerville, NJ | Hospital |
| Hunterdon Medical Center | Flemington, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jersey Shore Imaging Llc | 1355408212 | 118 |
| Flemington Radiology Associates Llc | 5294145819 | 55 |
| University Radiology Group Llc | 6608868500 | 213 |
| University Radiology-atlantic, Llc | 6901059864 | 124 |
| University Radiology At Robert Wood Johnson, Llc | 7810052388 | 120 |
| University Radiology At Trinitas Llc | 9133174634 | 89 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154367803 PECOS PAC ID: 6608868500 Enrollment ID: O20040331001432 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154367803 PECOS PAC ID: 6608868500 Enrollment ID: O20040501000035 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology At Trinitas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366526279 PECOS PAC ID: 9133174634 Enrollment ID: O20050317000492 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology At Robert Wood Johnson, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710131677 PECOS PAC ID: 7810052388 Enrollment ID: O20090217000263 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | Jersey Shore Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538304019 PECOS PAC ID: 1355408212 Enrollment ID: O20090319000362 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology-atlantic, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477802064 PECOS PAC ID: 6901059864 Enrollment ID: O20130102000114 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | Flemington Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942816475 PECOS PAC ID: 5294145819 Enrollment ID: O20201110000349 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Entity Name | University Radiology At Cooper Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669056248 PECOS PAC ID: 4587053699 Enrollment ID: O20211111000439 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samar J Hajj, MD 579a Cranbury Rd, East Brunswick, NJ 08816-5426 Ph: (732) 390-0040 | Samar J Hajj, MD 579a Cranbury Rd, East Brunswick, NJ 08816-5426 Ph: (732) 390-0040 |
News Archive
ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Now on Capsules, KHN's news blog, the latest installment of Blogwatch - Andrew Villegas rounds up what bloggers are saying about what might be at stake for Medicare, Medicaid and the health law.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.
Depending on how the decision shakes out, funding provided for the health law would be fair game during a time marked by difficult budget choices. Meanwhile, the GOP stays steady on its pledge to repeal the health law, or whatever remains of it.
› Verified 1 days ago